WO2014161811A1 - Lutschtablette zur behandlung von halsschmerz, heiserkeit und assoziiertem trockenen husten, sowie entzündlichen erkrankungen des mund und rachenraums - Google Patents
Lutschtablette zur behandlung von halsschmerz, heiserkeit und assoziiertem trockenen husten, sowie entzündlichen erkrankungen des mund und rachenraums Download PDFInfo
- Publication number
- WO2014161811A1 WO2014161811A1 PCT/EP2014/056437 EP2014056437W WO2014161811A1 WO 2014161811 A1 WO2014161811 A1 WO 2014161811A1 EP 2014056437 W EP2014056437 W EP 2014056437W WO 2014161811 A1 WO2014161811 A1 WO 2014161811A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- pharmaceutical dosage
- treatment
- drug
- astringent
- Prior art date
Links
- 206010011224 Cough Diseases 0.000 title claims abstract description 23
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 23
- 239000007937 lozenge Substances 0.000 title claims description 22
- 206010013952 Dysphonia Diseases 0.000 title claims description 9
- 208000010473 Hoarseness Diseases 0.000 title claims description 9
- 210000000214 mouth Anatomy 0.000 title abstract description 24
- 208000017574 dry cough Diseases 0.000 title abstract description 4
- 210000003800 pharynx Anatomy 0.000 title abstract 3
- 201000007100 Pharyngitis Diseases 0.000 title description 5
- 206010068319 Oropharyngeal pain Diseases 0.000 title description 3
- 239000002552 dosage form Substances 0.000 claims abstract description 45
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 230000007794 irritation Effects 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 39
- 229940037003 alum Drugs 0.000 claims description 15
- 239000003212 astringent agent Substances 0.000 claims description 15
- 210000004400 mucous membrane Anatomy 0.000 claims description 13
- 210000003097 mucus Anatomy 0.000 claims description 12
- 210000003300 oropharynx Anatomy 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 240000000982 Malva neglecta Species 0.000 claims description 5
- 235000000060 Malva neglecta Nutrition 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 4
- 244000208874 Althaea officinalis Species 0.000 claims description 3
- 235000006576 Althaea officinalis Nutrition 0.000 claims description 3
- 240000000377 Tussilago farfara Species 0.000 claims description 3
- 235000004869 Tussilago farfara Nutrition 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000009747 swallowing Effects 0.000 claims description 3
- 239000001648 tannin Substances 0.000 claims description 3
- 235000018553 tannin Nutrition 0.000 claims description 3
- 229920001864 tannin Polymers 0.000 claims description 3
- 208000025157 Oral disease Diseases 0.000 claims description 2
- 208000023668 Pharyngeal disease Diseases 0.000 claims description 2
- 235000001035 marshmallow Nutrition 0.000 claims description 2
- 208000030194 mouth disease Diseases 0.000 claims description 2
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 2
- 238000002636 symptomatic treatment Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 235000003805 Musa ABB Group Nutrition 0.000 claims 1
- 240000008790 Musa x paradisiaca Species 0.000 claims 1
- 235000015266 Plantago major Nutrition 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 abstract 1
- 229940066491 mucolytics Drugs 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 10
- 210000004877 mucosa Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 235000013736 caramel Nutrition 0.000 description 7
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 5
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000009702 powder compression Methods 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 4
- 208000019505 Deglutition disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920000715 Mucilage Polymers 0.000 description 3
- 229920001100 Polydextrose Polymers 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000000905 isomalt Substances 0.000 description 3
- 235000010439 isomalt Nutrition 0.000 description 3
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 3
- 210000003739 neck Anatomy 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000001259 polydextrose Substances 0.000 description 3
- 235000013856 polydextrose Nutrition 0.000 description 3
- 229940035035 polydextrose Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 235000021092 sugar substitutes Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 2
- 208000034309 Bacterial disease carrier Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 244000239204 Plantago lanceolata Species 0.000 description 2
- 235000010503 Plantago lanceolata Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 2
- 229960005164 acesulfame Drugs 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- 229940109275 cyclamate Drugs 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000000420 mucociliary effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- -1 2-ethylhexyl Chemical group 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 229920002097 Lichenin Polymers 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 206010061298 Mucosal haemorrhage Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- DBWPNOOPCWBBHH-UHFFFAOYSA-J O.O.O.O.O.O.O.O.O.O.[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O Chemical compound O.O.O.O.O.O.O.O.O.O.[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DBWPNOOPCWBBHH-UHFFFAOYSA-J 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010043521 Throat irritation Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108091008690 chemoreceptors Proteins 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108091008704 mechanoreceptors Proteins 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/10—Bryophyta (mosses)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- Lozenge for the treatment of sore throat, hoarseness and associated dry cough, as well as inflammatory diseases of the mouth and throat
- the present invention relates to a pharmaceutical dosage form containing a combination of (a) at least one astringent active ingredient and (b) at least one mucilaginous drug and its use for the prevention or treatment of
- the present invention relates to a pharmaceutical composition in the form of a suitable for sucking dosage form, wherein the composition comprises a combination of at least one astringent active substance with at least one second
- the oral mucosa serves to protect the underlying tissue and serves as a natural barrier against mechanical injury (lesions) and against the ingress of microorganisms and toxic substances. It moisturizes the oral cavity and moistens food to allow their digestion.
- the throat / throat area is lined with a mucous membrane whose essential
- Component is the epithelium.
- the epithelium is the interface between the human body and absorbed substances and forms a complex physicochemical barrier, which, complemented by the mucociliary apparatus, provides the first defense against pathogens. Mucus covers the epithelium and provides additional protection
- Mucosa in which it forms a semipermeable barrier, which prevents the exchange of
- the mucus is a complex, viscoelastic gel which is secreted by intraepithelial cells and mucous glands. Main ingredient of the mucus are mucins, large and highly charged glycoproteins that form the structural building of the mucosal barrier through cross-linking.
- mucociliary clearance is the number of cilia, their structure and activity, and their coordinated movement. Optimum function is ensured at 37 ° C and an absolute humidity of 44 mg / dm 3 (corresponds to 100% relative humidity). Cold, dry or overheated room air, as well as alcohol or nicotine affect the normal
- Mucosal function and may cause mucosal irritation, hoarseness, sore throat and dry cough. In such circumstances, bacterial colonization is favored and pulmonary infections may result.
- Dysphagia associated Also inflammations of the oral cavity such as Gingivitis, stomatitis or oral mucosal lesions have unpleasant symptoms for the affected patient.
- topical therapy for example in the form of oral and
- Throat purging, sprays or lozenges Throat purging, sprays or lozenges.
- additional systemic therapy e.g. by administering antibiotics.
- 1-hexadecylpyridinium chloride (international free name:
- CPC Certylpyridinium chloride
- astringent active substances in particular potassium aluminum sulfate decahydrate (international free name: alum), have proven useful. This is a salt traditionally used to treat lesions in the mouth, gingivitis or
- astringent effect it also reduces the colonization by germs and can mitigate pain by its decongestant effects.
- a disadvantage is the feeling of dry mouth caused by the astringent effect.
- mucous drugs active ingredients of natural origin
- active ingredients of natural origin e.g. so-called mucous drugs or their extracts, e.g. Icelandic moss (Liehen Islandicus).
- These mucous drugs contain high concentrations of polysaccharides, which form mucus in combination with water.
- They used in inflammatory diseases of the oropharynx in the form of e.g. Lozenges or sprays, they form a protective layer and moisten the mucous membrane.
- This additional mucus layer protects the sensitive mechano and chemoreceptors in the mucosa from external irritation and thereby reduces irritations such as irritation. Scratching, hoarseness and coughing.
- these drugs are used in the form of mono-preparations, but do not always achieve the desired success.
- the present invention is therefore an object of the invention to provide a pharmaceutical preparation in the form of a solid dosage form for the topical treatment of inflammatory diseases of the mouth and throat, which should at least largely avoids or mitigate the disadvantages of the prior art described above.
- a pharmaceutical preparation in the form of a solid dosage of at least one astringent agent (eg alum) with at least one mucilaginous drug and / or its extract (eg Icelandic moss) is particularly suitable.
- a composition in the form of lozenges prepared by compression of powder mixtures or based on hard caramels, which can be used topically in painful or painful inflammatory diseases of the mouth and throat.
- the present invention relates to a pharmaceutical dosage form containing a combination of (a) at least one astringent active ingredient and (b) at least one mucilaginous drug.
- the aforementioned combination is particularly suitable for the prevention and treatment, especially for the symptomatic prevention or treatment of inflammatory
- the present invention further relates to the use of the pharmaceutical dosage form according to the invention for the prevention or treatment of inflammatory diseases of the oropharynx.
- Pharmaceutical dosage form for the treatment of painful irritation of the mucous membranes in the mouth and throat and associated cough is provided.
- the present invention relates to the combination according to the invention of (a) at least one astringent active ingredient and (b) at least one mucous drug, and their use in the prevention or treatment of inflammatory diseases of the oropharynx and / or their use in the treatment of painful Irritation of the mucous membranes in the mouth and throat area and associated coughing.
- the combination according to the invention based on at least one astringent active ingredient and at least one mucous drug results in high efficacy at the same time a good compatibility along with the greatest possible prevention of side effects.
- the principle of action of the composition according to the invention is based on purely physical or physicochemical processes.
- the basic principle of the present invention is based on a targeted combination of astringent agents on the one hand and active ingredients based on mucous drugs on the other hand, the inventors have found that the effectiveness of astringent drugs on the one hand and mucous drugs on the other hand, with reference to the above
- combination describes at least two active agents selected from (a) astringent agents and (b) mucous drugs that are in a mutually acceptable ratio for co-administration.
- mucous drug as used herein includes the mucous drug whose
- Icelandic moss as used herein includes Icelandic moss, its ingredients and extracts thereof.
- Icelandic moss (Liehen islandicus), mallow (Malva sylvestris), ribwort plantain (Plantago lanceolata), marshmallow (Althaea officinalis) and coltsfoot (Tussilago farfara), as well as their mixtures, are particularly suitable as slime drugs used in accordance with the invention.
- Icelandic moss especially in the form of an extract, is used.
- astringent agent includes agents that are dehydrating, hemostatic and anti-inflammatory when exposed to skin or mucous membranes, particularly alum, tannin, policingules and silver nitrate or mixtures thereof, preferably alum.
- a specific embodiment of the present invention relates to a pharmaceutical dosage form according to any one of the preceding claims consisting of (a) at least one astringent agent; (b) at least one mucilaginous drug and (c) at least one further excipient.
- pharmaceutical dosage form as used herein particularly includes common solid pharmaceutical dosage forms, such as lozenges, for example, prepared by powder compression or hard caramel based.
- auxiliaries are, in particular, tableting aids and fillers, for example isomalt, fructose and / or glucose syrup, silicon dioxide, talcum, magnesium stearate, macrogol, polydextrose or xanthan gum, sweeteners, for example
- Sugar substitutes in particular isomalt, sorbitol, polydextrose, maltitol or isomaltitol, sweeteners, for example aspartame, acesulfame, cyclamate, saccharin or xylitol, flavors, dyes and / or stabilizers, for example tartaric acid or citric acid.
- the proportion by weight of the auxiliaries used is usually in a range from 50 to 99.5 wt .-%, preferably from 75 to 99 wt .-%, particularly preferably from 85 to 95 wt .-%, each based on the total weight of the pharmaceutical dosage form.
- Icelandic moss is used as a mucus drug. Icelandic moss is preferably used as an extract.
- Suitable extracts of Icelandic moss are obtained, for example, by aqueous, alcoholic or aqueous-alcoholic extraction and, if appropriate, subsequent drying. These extracts usually consist mainly of mucus-forming
- the mucilage contains the extract lichen acids which have a slight antimicrobial effect. Compared to drug, the processing of extracts is simplified.
- mallow is used as a mucus drug.
- Mallow is preferably used here as an extract.
- Suitable extracts of mallow are obtained for example by aqueous, alcoholic or aqueous-alcoholic extraction and optionally subsequent drying. These extracts usually consist mostly of mucus. These consist of the crosslinked individual building blocks glucose, arabinose, rhamnose and glactose together. The content in the extract is many times higher than the pure drug, which improves the therapeutic effect.
- the pharmaceutical dosage form according to the invention usually contain the mucus drug in an amount of from 1 mg to 500 mg, preferably from 10 mg to 250 mg, particularly preferably from 50 mg to 200 mg.
- the proportion by weight of the mucous drug used is usually in a range from 1 to 50% by weight, preferably from 2 to 25% by weight, particularly preferably from 5 to 10% by weight, in each case based on the total weight of the pharmaceutical dosage form
- alum is used as an astringent agent.
- tannin is used as an astringent active ingredient.
- the pharmaceutical dosage form according to the invention usually contains the astringent active ingredient in an amount of from 0.1 mg to 50 mg, preferably from 0.5 mg to 20 mg, particularly preferably from 1 mg to 10 mg.
- the proportion by weight of the astringent active substance used is usually in a range from 0.01 to 5 wt .-%, preferably from 0.05 to 2 wt .-%, particularly preferably from 0.1 to 1 wt .-%, each based on the total weight of the pharmaceutical
- a preferred embodiment of the present invention relates to the combination of Icelandic moss as a mucus drug and alum as an astringent active ingredient.
- Icelandic moss is used here usually in an amount of 1 mg to 500 mg, preferably in an amount of 10 mg to 250 mg, more preferably in an amount of 50 mg to 200 mg.
- Alum is usually used in an amount of 0.1 mg to 20 mg, preferably in an amount of 1 mg to 15 mg, more preferably in an amount of 3 to 10 mg.
- the weight ratio of Icelandic moss to alum is usually in the range from 5: 1 to 50: 1, preferably from 10: 1 to 25: 1, particularly preferably from 15: 1 to 20: 1.
- the weight proportion of Icelandic moss and alum is usually in a range of 0.5 to 50 wt .-%, preferably from 1 to 25 wt .-%, particularly preferably from 5 to 15% by weight, each based on the total weight of the pharmaceutical dosage form
- the pharmaceutical dosage form according to the invention is preferably provided as a lozenge.
- Suitable lozenges can be prepared, for example, by powder compression or on a hard caramel basis.
- the total weight of the pharmaceutical dosage form is usually in a range from 500 mg to 5000 mg, preferably from 750 mg to 4000 mg, particularly preferably from 1000 mg to 3000 mg.
- the pharmaceutical dosage form according to the invention is usually administered up to 20 times a day, preferably up to 12 times, more preferably up to 8 times a day.
- the combination according to the invention is suitable for the prevention or treatment of inflammatory diseases of the oropharynx. Accordingly, the pharmaceutical dosage form according to the invention is also suitable for this use.
- the combination according to the invention is particularly suitable for the prevention or
- the pharmaceutical dosage form according to the invention is also suitable for this use.
- the combination according to the invention is also particularly suitable for the symptomatic treatment of inflammatory diseases of the oropharynx.
- the pharmaceutical according to the invention is also suitable
- the combination according to the invention is also particularly suitable for the treatment of inflammation and / or pain in inflammatory diseases of the oropharynx. Accordingly, the pharmaceutical dosage form according to the invention is also suitable for this use.
- the combination according to the invention is also particularly suitable for the treatment of irritative cough, especially in inflammatory diseases of the oropharynx. Accordingly, the pharmaceutical according to the invention is also suitable
- the combination of the invention is also particularly suitable for the treatment of dysphagia, especially in inflammatory diseases of the mouth and throat. Accordingly, the pharmaceutical dosage form according to the invention is also suitable for this use.
- the combination according to the invention is also particularly suitable for regaining voice limited by hoarseness and pain, especially in inflammatory diseases of the oropharynx. Accordingly, the pharmaceutical dosage form according to the invention is also suitable for this use.
- the combination according to the invention is particularly suitable for the topical administration of the active ingredients. Accordingly, the pharmaceutical dosage form according to the invention is also suitable for this use.
- the combination according to the invention is also particularly suitable for the treatment of painful irritations of the mucous membranes in the mouth and throat area and associated coughing. Accordingly, the pharmaceutical dosage form according to the invention is also suitable for this use.
- the combination according to the invention helps to calm the irritated and / or inflamed mucous membrane of the mouth and throat and relieves the neck pain.
- the combination of the invention helps in the regeneration of the mucous membranes in cold-related symptoms.
- the combination according to the invention helps in the treatment of sore throats
- the combination of the invention helps alleviate the symptoms of throat inflammation and irritation, such as dry, itchy, scratchy necks.
- the combination of the invention helps protect the neck against further irritation.
- the combination of the invention acts as a protective film of the irritated mucosa against bacterial colonization.
- the combination according to the invention soothes the oral and pharyngeal mucosa and thus helps to break the cycle of throat complaints and dry coughing.
- the combination according to the invention helps to reduce the symptoms of dry coughing and relieves the coughing stimulus.
- the combination according to the invention helps to calm and moisten the neck and thus relieves the cough.
- the combination according to the invention helps with difficulty swallowing.
- the combination according to the invention helps with hoarseness.
- Another specific subject of the present invention relates to the combination of (a) at least one astringent agent and (b) at least one mucilaginous drug for use in the prevention or treatment of inflammatory diseases of the oropharynx.
- Another specific object of the present invention relates to a combination of (a) at least one astringent agent and (b) at least one mucous drug for use in the treatment of painful irritation of the mucous membranes in the mouth and throat and associated cough EXAMPLES
- Lozenges based on an astringent agent in combination with various mucous drugs Lozenges based on an astringent agent in combination with various mucous drugs.
- compositions are prepared in the form of lozenges based on powder compression or hard caramel base. For the compressed
- Lozenges may preferably sugar substitutes, in particular isomalt, sorbitol or polydextrose, used for the hard caramel base fructose and / or glucose syrup, sugar-free variant sugar substitutes, especially sugar alcohols, preferably maltitol or isomaltitol.
- sugar-free variant sugar substitutes especially sugar alcohols, preferably maltitol or isomaltitol.
- Variable amounts of sweeteners e.g., aspartame, acesulfame, cyclamate, saccharin, or xylitol
- Other auxiliaries and active ingredients are incorporated into the matrix and the lozenges are manufactured in a manner known per se.
- the excipients are weighed according to the recipe and mixed with the matrix.
- these can be added via a further granulation step. Subsequently, powder or granules are pressed into lozenges.
- the excipients or active substances can optionally be pressed together on one or more layers together or separately (1, 2 or 3-layer tablets).
- the raw materials are mixed according to the recipe and mixed into the heated hard caramel base.
- Heat-sensitive auxiliaries and / or active ingredients in particular
- lozenge formulation Sugar-free lozenges with different amounts of astringent drugs and mucous drugs are produced in these types, for example, as shown in the following tables:
- Table 1 1-layer lozenge prepared by powder compression with 5 mg alum and 80 mg Icelandic moss extract
- Table 3 2-layer lozenge prepared by powder compression with 5 mg alum and 80 mg Icelandic moss extract
- Throat area and partly associated with coughing were treated with the lozenges described in the previous production examples without additional systemic therapy.
- Ten patients were treated with the formulation described in Table 4, with up to six tablets administered over a period of three days (Group A). 10 others were treated with a commercial preparation only with alum (9 mg per lozenge) over three days with up to six tablets (group B). A further 10 patients were treated with a commercial single preparation
- the non-inventive preparation of group B showed an improvement of the inflammatory and pain symptoms of the mucosa.
- the symptoms of hoarseness and dryness in the mouth and the associated irritant cough showed little to no improvement in group B.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112015020019-2A BR112015020019B1 (pt) | 2013-04-02 | 2014-03-31 | forma de dosagem farmacêutica e seu uso |
CN201480017390.1A CN105050610A (zh) | 2013-04-02 | 2014-03-31 | 用于治疗咽喉痛、声嘶及相关的干咳以及治疗口腔和咽的炎性疾病的锭剂 |
JP2016505784A JP6491191B2 (ja) | 2013-04-02 | 2014-03-31 | 咽喉炎、嗄声及び関連の空咳、並びに口腔及び咽頭腔の炎症性疾患の治療用ロゼンジ剤 |
EA201500992A EA030913B1 (ru) | 2013-04-02 | 2014-03-31 | Леденец для лечения боли в горле, охриплости голоса и связанного с ней сухого кашля и воспалительных заболеваний полости рта и глотки |
ES14715256T ES2717663T3 (es) | 2013-04-02 | 2014-03-31 | Comprimido para chupar para el tratamiento del dolor de garganta, ronquera y tos seca asociada, así como afecciones inflamatorias de la boca y de la cavidad faríngea |
CA2906272A CA2906272A1 (en) | 2013-04-02 | 2014-03-31 | Lozenge for treating sore throat, hoarseness and associated dry cough, and inflammatory diseases of the oral and pharyngeal cavity |
AU2014247141A AU2014247141B2 (en) | 2013-04-02 | 2014-03-31 | Lozenge for treating a sore throat, hoarseness, and associated dry cough and for treating inflammatory diseases of the oral cavity and of the pharynx |
EP14715256.5A EP2981275B1 (de) | 2013-04-02 | 2014-03-31 | Lutschtablette zur behandlung von halsschmerz, heiserkeit und assoziiertem trockenen husten, sowie entzündlichen erkrankungen des mund und rachenraums |
MX2015013934A MX362885B (es) | 2013-04-02 | 2014-03-31 | Pastilla para tratar garganta irritada, ronquera y tos seca asociada, y enfermedades inflamatorias de la cavidad oral y faringea. |
KR1020157031402A KR102218148B1 (ko) | 2013-04-02 | 2014-03-31 | 인후통, 쉰목소리 및 관련 마른 기침 치료용, 및 구강 및 인두강의 염증성 질환 치료용 로젠지제 |
PH12015502274A PH12015502274B1 (en) | 2013-04-02 | 2015-09-30 | Lozenge for treating a sore throat, hoarseness, and associated dry cough and for treating inflammatory diseases of the oral cavity and of the pharynx |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13161902 | 2013-04-02 | ||
EP13161902.5 | 2013-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014161811A1 true WO2014161811A1 (de) | 2014-10-09 |
Family
ID=47997281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/056437 WO2014161811A1 (de) | 2013-04-02 | 2014-03-31 | Lutschtablette zur behandlung von halsschmerz, heiserkeit und assoziiertem trockenen husten, sowie entzündlichen erkrankungen des mund und rachenraums |
Country Status (13)
Country | Link |
---|---|
US (2) | US20140294995A1 (de) |
EP (1) | EP2981275B1 (de) |
JP (1) | JP6491191B2 (de) |
KR (1) | KR102218148B1 (de) |
CN (1) | CN105050610A (de) |
AU (1) | AU2014247141B2 (de) |
BR (1) | BR112015020019B1 (de) |
CA (1) | CA2906272A1 (de) |
EA (1) | EA030913B1 (de) |
ES (1) | ES2717663T3 (de) |
MX (1) | MX362885B (de) |
PH (1) | PH12015502274B1 (de) |
WO (1) | WO2014161811A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3144752A1 (fr) | 2023-01-10 | 2024-07-12 | Song Huang | Utilisation de polysulfate de pentosane pour le traitement de la toux seche |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6163258B2 (ja) | 2013-05-31 | 2017-07-12 | 北京有色金属研究総院General Research Institute for Nonferrous Metals | 希土類永久磁石粉末、それを含む接着性磁性体及び当該接着性磁性体を応用した素子 |
IT201700016964A1 (it) * | 2017-02-15 | 2018-08-15 | Aboca Spa Societa Agricola | Composizione per la tosse |
EP3459368A1 (de) * | 2017-09-20 | 2019-03-27 | Geophyt S.r.L. | Lebensmittelintegrator für antineoplastische therapien |
EP4059508A1 (de) * | 2021-03-19 | 2022-09-21 | Johnson & Johnson Consumer Inc. | Verfahren zur verwendung von zusammensetzungen mit einem extrakt aus isländischem moos |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011001321A (ja) * | 2009-06-19 | 2011-01-06 | Wakan Shoyaku Kenkyusho:Kk | 咽頭炎用及びインフルエンザ予防・治療用の経口投与組成物 |
EP2361623A1 (de) * | 2010-02-09 | 2011-08-31 | Novintethical Pharma, SAGL | Zusammensetzung mit einem Polyphenolsalz und zugehörige Verwendung |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3042917B2 (ja) * | 1991-09-12 | 2000-05-22 | 日本化薬株式会社 | ペースト及びペースト製剤 |
CN1283296C (zh) * | 2004-04-29 | 2006-11-08 | 吕文晓 | 一种咽喉保健茶及其制备方法 |
US20070178123A1 (en) * | 2006-01-27 | 2007-08-02 | Deborah Levenson | Flavor-enhancing compositions, method of manufacture, and methods of use |
DE202006009570U1 (de) * | 2006-06-16 | 2007-07-26 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Reizlinderndes Hustenmittel |
WO2011092835A1 (ja) * | 2010-01-29 | 2011-08-04 | パナセア ディシンフェクタント カンパニー リミテッド | 持続性口腔用殺菌消毒液 |
-
2014
- 2014-03-31 EA EA201500992A patent/EA030913B1/ru not_active IP Right Cessation
- 2014-03-31 KR KR1020157031402A patent/KR102218148B1/ko active IP Right Grant
- 2014-03-31 CN CN201480017390.1A patent/CN105050610A/zh active Pending
- 2014-03-31 MX MX2015013934A patent/MX362885B/es active IP Right Grant
- 2014-03-31 ES ES14715256T patent/ES2717663T3/es active Active
- 2014-03-31 BR BR112015020019-2A patent/BR112015020019B1/pt active IP Right Grant
- 2014-03-31 AU AU2014247141A patent/AU2014247141B2/en active Active
- 2014-03-31 JP JP2016505784A patent/JP6491191B2/ja active Active
- 2014-03-31 WO PCT/EP2014/056437 patent/WO2014161811A1/de active Application Filing
- 2014-03-31 EP EP14715256.5A patent/EP2981275B1/de active Active
- 2014-03-31 CA CA2906272A patent/CA2906272A1/en not_active Abandoned
- 2014-04-01 US US14/242,121 patent/US20140294995A1/en not_active Abandoned
-
2015
- 2015-09-30 PH PH12015502274A patent/PH12015502274B1/en unknown
-
2016
- 2016-03-10 US US15/066,604 patent/US10004774B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011001321A (ja) * | 2009-06-19 | 2011-01-06 | Wakan Shoyaku Kenkyusho:Kk | 咽頭炎用及びインフルエンザ予防・治療用の経口投与組成物 |
EP2361623A1 (de) * | 2010-02-09 | 2011-08-31 | Novintethical Pharma, SAGL | Zusammensetzung mit einem Polyphenolsalz und zugehörige Verwendung |
Non-Patent Citations (2)
Title |
---|
DATABASE TCM [online] sipo; 26 January 2005 (2005-01-26), LV WENXIAO, ZHONG WEIDONG: "A kind of laryngopharynx health tea and its preparation method/A kind of new chinese medicinal composition and its preparation of medical tea, which can used for the prevention and treatment of acute/chronic pharyngolaryngitis, stomatitis and upper respiratory infection", XP002708380, Database accession no. CN1569192 * |
DATABASE WPI Week 201105, Derwent World Patents Index; AN 2011-A54615, XP002708379 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3144752A1 (fr) | 2023-01-10 | 2024-07-12 | Song Huang | Utilisation de polysulfate de pentosane pour le traitement de la toux seche |
WO2024149719A1 (fr) | 2023-01-10 | 2024-07-18 | Song Huang | Utilisation de polysulfate de pentosane pour le traitement de la toux seche |
Also Published As
Publication number | Publication date |
---|---|
MX362885B (es) | 2019-02-22 |
BR112015020019A2 (pt) | 2017-07-18 |
US20140294995A1 (en) | 2014-10-02 |
AU2014247141A1 (en) | 2015-09-10 |
AU2014247141B2 (en) | 2018-07-05 |
JP6491191B2 (ja) | 2019-03-27 |
EA030913B1 (ru) | 2018-10-31 |
KR20150136540A (ko) | 2015-12-07 |
PH12015502274A1 (en) | 2016-02-01 |
US20160193267A1 (en) | 2016-07-07 |
EA201500992A1 (ru) | 2016-03-31 |
EP2981275A1 (de) | 2016-02-10 |
BR112015020019B1 (pt) | 2021-05-18 |
EP2981275B1 (de) | 2019-01-09 |
KR102218148B1 (ko) | 2021-02-23 |
JP2016515594A (ja) | 2016-05-30 |
CN105050610A (zh) | 2015-11-11 |
CA2906272A1 (en) | 2014-10-09 |
ES2717663T3 (es) | 2019-06-24 |
MX2015013934A (es) | 2015-12-08 |
PH12015502274B1 (en) | 2016-02-01 |
US10004774B2 (en) | 2018-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2981275B1 (de) | Lutschtablette zur behandlung von halsschmerz, heiserkeit und assoziiertem trockenen husten, sowie entzündlichen erkrankungen des mund und rachenraums | |
DE102004052308B4 (de) | Octenidinhaltige Lutschtabletten gegen entzündliche Erkrankungen des Mund- und Rachenraums | |
DE102013000700A1 (de) | Zusammensetzung, insbesondere pharmazeutische Zusammensetzung, insbesondere zur Verabreichung bei Heiserkeit und Halsschmerzen | |
EP2367557A1 (de) | Zusammensetzung zur behandlung von entzündlichen erkrankungen des mund- und rachenraums | |
EP1871340B1 (de) | Reizlinderndes hustenmittel enthaltend extrakte aus isländischem moos und malve sowie zinkverbindungen | |
EP1639998B1 (de) | Schleimdrogenbasierte Lutschtablette gegen entzündliche Erkrankungen des Mund- und Rachenraums | |
DE202006011920U1 (de) | Zusammensetzung zur Behandlung von Rhinitis | |
EP2617412B1 (de) | Zusammensetzung für die topische Behandlung | |
WO2017028976A1 (de) | Zusammensetzung für die behandlung des hals-/rachenraums | |
WO2017028977A1 (de) | Zusammensetzung für die behandlung des hals-/rachenraums | |
DE202006008541U1 (de) | Reizlinderndes Hustenmittel | |
DE202004016077U1 (de) | Lutschtablette gegen entzündliche Erkrankungen des Mund- und Rachenraums | |
DE202004016078U1 (de) | Schleimdrogenbasierte Lutschtablette gegen entzündliche Erkrankungen des Mund- und Rachenraums | |
DE202005009181U1 (de) | Reizlinderndes Hustenmittel | |
DE102011122236A1 (de) | Zusammensetzung für die topische Anwendung bei entzündlichen Erkrankungen der Haut und/oder Schleimhaut | |
DE202006009570U1 (de) | Reizlinderndes Hustenmittel | |
DE202005018338U1 (de) | Lutschtablette gegen Hustenreiz und Heiserkeit | |
DE102004050589A1 (de) | Lutschtablette gegen entzündliche Erkrankungen des Mund- und Rachenraums | |
WO2011104301A2 (de) | Zusammensetzung zur behandlung von reizhusten und/oder halsschmerzen | |
UA78642C2 (en) | Absorbable tablet based on mucus-producing medicinal plants intended for topical treatment of inflammatory diseases of oral cavity and pharynx |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480017390.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14715256 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201505259 Country of ref document: ID |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015020019 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2014247141 Country of ref document: AU Date of ref document: 20140331 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2906272 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12015502274 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2016505784 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/013934 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014715256 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20157031402 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201500992 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 112015020019 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150820 |